Back to top
more

Viatris (VTRS)

(Delayed Data from NSDQ)

$10.89 USD

10.89
7,069,885

+0.09 (0.83%)

Updated Jul 10, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Viatris (VTRS) Up 5.1% Since Last Earnings Report: Can It Continue?

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Viatris (VTRS) Q3 Earnings Beat, Complex Generics Sales Dip

Viatris (VTRS) third-quarter earnings beat estimates. While brands maintain business, the Complex generics business performs below management's expectations.

Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally

Thervance (TBPH) incurs a narrower-than-expected loss in the third quarter of 2023. Revenues marginally beat estimates.

Viatris (VTRS) Beats Q3 Earnings Estimates

Viatris (VTRS) delivered earnings and revenue surprises of 5.41% and 1.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Viatris (VTRS) Ahead of Earnings?

Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.

Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store?

Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses.

Viatris (VTRS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Viatris (VTRS) is Poised to Beat Earnings Estimates Again

Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Viatris (VTRS) to Divest Some More Businesses, Shares Gain

Viatris (VTRS) enters into agreements to divest its remaining businesses previously planned for 2023. Its shareholders are upbeat about the same.

Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent

Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

Smart Beta ETF report for RSPH

Why Is Viatris (VTRS) Down 4.8% Since Last Earnings Report?

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Viatris (VTRS) Gets Tentative Approval for HIV Regimen for Kids

Viatris (VTRS) obtains tentative approval from the FDA for a pediatric formulation of abacavir/dolutegravir/lamivudine, a once-daily treatment for children living with HIV.

Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss

Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.

Company News for Aug 8, 2023

Companies in The News Are: KKR,SAGE,VTRS,FRPT

Viatris (VTRS) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Viatris (VTRS) Q2 Earnings Beat, Generics Business Grows

Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance.